A wave of new European healthcare legislations is on the way. The regulatory landscape for pharmaceuticals, biotechnology and medical devices is evolving fast. In a recent update, the Belgian Federal Agency for Medicines and Health Products (FAMHP) summarised the major initiatives. Together, they will touch nearly every activity in the life sciences sector.
Five initiatives to watch
- The Biotech Act aims to strengthen Europe’s biotechnology sector through support for innovation, clinical research and strategic investment.
- The proposed MDR and IVDR revisions focus on simplifying and modernising the framework for medical devices and in vitro diagnostics while maintaining patient safety standards.
- The Critical Medicines Act is designed to improve supply chain resilience and reduce the risk of medicine shortages.
- The new EU Pharmaceutical Legislation is the most significant reform of pharmaceutical regulation since 2004, focused on innovation, access to medicines and supply security.
- Future changes to the Audiovisual Media Services Directive may bring stricter requirements for online health information, influencer marketing and pharmaceutical advertising.
What this means for companies
These changes will affect almost everything: product development, regulatory strategy, marketing authorisations, lifecycle management, supply chains, quality systems and communication practices. So prepare actively. Map which initiatives touch your portfolio and when. Companies that do this now will be better positioned than those that wait for the final texts.
How MPCA can help
We monitor European and national regulatory developments daily and translate them into practical actions for our clients: regulatory strategy and compliance, registration dossiers and submissions, lifecycle management, MDR and IVDR activities, quality assurance and regulatory impact assessments. See also the FAMHP’s overview of upcoming European legislation.
This article is for general information and reflects the situation at the time of writing. Always consult the official EU and FAMHP publications for binding requirements.